“Budget Impact Analysis of Dabigatran Compared With Rivaroxaban in the Prevention of the Thromboembolic Risk in Patients With Non-Valvular Atrial Fibrillation”. Farmeconomia. Health Economics and Therapeutic Pathways 18, no. 1 (November 14, 2017). Accessed December 28, 2025. https://journals.seedstm.com/index.php/FE/article/view/1327.